Merck and Ridgeback Biotherapeutics Covid-19 pill less effective
Merck has shared these additional analyses with the FDA and they will be presented to the FDA’s Antimicrobial Drugs Advisory Committee on Nov. 30th
Merck has shared these additional analyses with the FDA and they will be presented to the FDA’s Antimicrobial Drugs Advisory Committee on Nov. 30th
The aim is to create an awareness programme that will drive diabetic patients to get their eyes tested regularly
The appraisal of the applications has been carried out based on the ranking methodology laid down in the operational guidelines of the Scheme
Market demand for significant volumes and quality of biopharma products would drive continuous manufacturing technologies
Fyarro is the first and only approved therapy for adults for the treatment of malignant PEComa in adults
Owkin builds best-in-class predictive biomedical AI models and robust data sets
Contribution from the top five therapies stood at 58% of IPM in October 2021. These therapies are cardiac, anti-infectives, gastro-intestinal, anti-diabetic and vitamins
The partnership will help advance GreenLight's messenger RNA Covid-19 vaccine candidate
The companies expect to manufacture over 80 million does of the Covid-19 vaccine in 2022
The company is marketing the kit under the brand name CoviFind and it can detect the infection in 15 minutes
Subscribe To Our Newsletter & Stay Updated